Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Bisphosphonate treatment in patients with early breast cancer has become part of care, but the optimal treatment duration is still unclear. OBJECTIVE: To compare 2 vs 5 years of zoledronate treatment following adjuvant chemotherapy in patients with early breast cancer. DESIGN, SETTING, A...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:JAMA Oncol
Hoofdauteurs: Friedl, Thomas W. P., Fehm, Tanja, Müller, Volkmar, Lichtenegger, Werner, Blohmer, Jens, Lorenz, Ralf, Forstbauer, Helmut, Fink, Visnja, Bekes, Inga, Huober, Jens, Jückstock, Julia, Schneeweiss, Andreas, Tesch, Hans, Mahner, Sven, Brucker, Sara Y., Heinrich, Georg, Häberle, Lothar, Fasching, Peter A., Beckmann, Matthias W., Coleman, Robert E., Janni, Wolfgang, Rack, Brigitte
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Medical Association 2021
Onderwerpen:
Original Investigation
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8227465/
https://ncbi.nlm.nih.gov/pubmed/34165508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.1854
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items